UPB earnings: real EPS beat/miss history, analyst consensus Hold, P/E -2.26. Updated 2026-07-23.
Upstream Bio (UPB) Research Hub
Upstream Bio (UPB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 5.73 USD (-3.86%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.26, market cap 0.35B. This hub links to the full technical, earnings and options research available for UPB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.73 USD (-3.86%) |
| 52-week range | 5.65 USD – 8 USD |
| Trend regime | Range |
| 14-day RSI | 28.4 (Oversold) |
| Trailing P/E | -2.26 |
| Market cap | 0.35B |
| Dividend yield | 0.00% |
Available research for UPB
Covered Call on UPB: how it works, illustrative setup around the real 5.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on UPB: how it works, illustrative setup around the real 5.73 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on UPB: how it works, illustrative setup around the real 5.73 USD price, max profit/loss, breakeven and when to use it. Educational.
UPB technical analysis: range, last 5.73 USD, RSI 28.4, 52w range 5.65 USD–8 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is UPB in?
Upstream Bio (UPB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is UPB in an uptrend or downtrend?
As of 2026-09-11, UPB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is UPB's trailing P/E ratio?
UPB's trailing P/E is -2.26, with a market cap of 0.35B. See the earnings research page for full valuation detail.